A zoster mRNA vaccine SYS6017

BIOLOGICAL2 trials

Sponsors

CSPC Megalith Biopharmaceutical Co.,Ltd.

Conditions

Herpes Zoster

Phase 1

Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More

Not yet recruitingNCT06954818

CSPC Megalith Biopharmaceutical Co.,Ltd.Herpes Zoster

Start: 2025-05-10End: 2026-11-10Target: 200Updated: 2025-05-08

Phase 2

Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above

Not yet recruitingNCT07354659

CSPC Megalith Biopharmaceutical Co.,Ltd.Herpes Zoster

Start: 2026-01-10End: 2027-05-31Target: 800Updated: 2026-01-21